Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.59 |
| ▸ | GRM5 | P41594 | 11/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15176153 | 0.86 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL30439311 | 0.86 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL31639564 | 0.86 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL24165372 | 0.85 | GRM1 (0.53) | GRM1GRM5PDK4NAMPTCNR1 | |
| SCHEMBL30648008 | 0.85 | GRM1 (0.53) | GRM1GRM5PDK4NAMPTCNR1 | |
| SCHEMBL24880472 | 0.85 | GRM1 (0.61) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL24891853 | 0.84 | GRM1 (0.57) | GRM1GRM5PDK4NAMPTWNT3A | |
| SCHEMBL31590064 | 0.83 | GRM1 (0.56) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL2264461 | 0.83 | GRM1 (0.56) | GRM1GRM5PDK4NAMPTWNT3A | |
| SCHEMBL29907164 | 0.82 | GRM1 (0.55) | GRM1GRM5PDK4NAMPTCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109708-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | CELGENE CORP (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4661875-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2024167950-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | CELGENE CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2024-01-11 | — | — | US | disclosed |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| EP-4105208-A1 | 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| EP-3027600-B1 | 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2022-04-06 | — | — | EP | disclosed |
| US-20190160062-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-20160184305-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009085185-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, PMP22 | GRM1 1712/4885GRM5 1006/4885PDK4 2533/4885 |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | CDK4, CDKL4, CDK2 | GRM1 2980/4885GRM5 1673/4885PDK4 83/4885 |
| US-20160184305-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, SCN5A, SF3B5 | GRM1 1956/4885GRM5 464/4885PDK4 2684/4885 |
| US-20190160062-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, PMP22 | GRM1 1712/4885GRM5 1006/4885PDK4 2533/4885 |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, PMP22 | GRM1 1712/4885GRM5 1006/4885PDK4 2533/4885 |
| US-20260109708-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | PSME2, MKRN3, RPS6KA2 | GRM1 1553/4885GRM5 2280/4885PDK4 1405/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | GRM1 693/4885GRM5 305/4885PDK4 2156/4885 |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | CDK4, CDKL4, CDK2 | GRM1 2980/4885GRM5 1673/4885PDK4 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.